血清SBEM、hMAM和CEACAM19水平在乳腺癌早期诊断中的临床意义  

Clinical significances of serum levels of SBEM, hMAM and CEACAM19 in early diagnosis of breast cancer

作　　者：于秀艳[1] 田春迎[1] 张晓伟[1] 吴雪峰[1] YU Xiuyan;TIAN Chunying;ZHANG Xiaowei;WU Xuefeng(Department of Clinical Laboratory,Tumor Hospital,Jilin Province,Changchun 130012,China)

机构地区：[1]吉林省肿瘤医院检验科,吉林长春130012

出　　处：《吉林大学学报（医学版）》2021年第6期1518-1525,共8页Journal of Jilin University：Medicine Edition

基　　金：吉林省卫计委科研基金项目(2018J025)。

摘　　要：目的:检测乳腺癌患者血清乳腺上皮小黏蛋白(SBEM)、人乳腺珠蛋白(hMAM)和癌胚抗原相关细胞黏附分子19(CEACAM19)水平,阐明各指标在乳腺癌早期诊断中的意义及其与患者临床病理参数的关系。方法:选取80例乳腺癌患者作为乳腺癌组、58例乳腺良性病变患者作为乳腺良性病变组和54名健康女性作为健康对照组。采用ELISA法检测3组研究对象血清SBEM、hMAM和CEACAM19水平,采用受试者工作特征曲线(ROC)分析各指标诊断乳腺癌的曲线下面积(AUC)、cut-off值、灵敏度和特异度。结果:乳腺癌组患者血清SBEM、hMAM和CEACAM19水平均明显高于乳腺良性病变组和健康对照组(P<0.05)。与TNM分期Ⅰ-Ⅱ期比较,TNM分期Ⅲ-Ⅳ期乳腺癌患者血清SBEM、hMAM和CEACAM19水平均明显升高(P<0.05);与淋巴结转移阴性组比较,淋巴结转移阳性组乳腺癌患者血清SBEM、hMAM和CEACAM19水平均明显升高(P<0.05)。SBEM、hMAM、CEACAM19单独及联合检测诊断乳腺癌的AUC、灵敏度和特异度分别为0.868、80.0%和88.4%;0.809、70.0%和80.4%;0.756、97.5%和50.9%;0.913、82.5%和90.2%,联合检测的诊断效能最佳。结论:血清SBEM、hMAM和CEACAM19联合检测筛查乳腺癌具有较高的灵敏度和特异度,可提高乳腺癌患者的早期诊断效能。Objective:To detect the levels of small breast epithelial mucin(SBEM),human mammaglobin(hMAM),and carcinoembryonic antigen-related cell adhesion molecule 19(CEACAM19)in serum of the patients with breast cancer,and to clarify the significances of these indicators in the early diagnosis of breast cancer and their relationships with the clinicopathological parameters of the patients.Methods:A total of 80 patients with breast cancer were selected as breast cancer group,58 patients with benign breast disease were selected as benign breast disease group,and 54 healthy women were selected as healthy control group.The serum levels of SBEM,hMAM,and CEACAM19 of the subjects in three groups were measured by ELISA method.The receiver operating characteristic curve(ROC)was used to analyze the area under curve(AUC),cut-off value,sensitivity and specificity of these indexes in diagnosis of breast cancer.Results:The levels of serum SBEM,hMAM,and CEACAM19 of the patients in breast cancer group were significantly higher than those in benign breast lesion group and healthy control group(P<0.05).Compared with TNMⅠ-Ⅱstages,the levels of serum SBEM,hMAM,and CEACAM19 in the patients with TNMⅢ-Ⅳstages breast cancer were significantly increased(P<0.05).Compared with negative lymph node metastasis group,the serum levels of SBEM,hMAM,and CEACAM19 in the breast cancer patients with positive lymphnode metastasis were significantly increased(P<0.05).The AUC,sensitivities,and specificities of SBEM,hMAM,CEACAM19 and SBEM+hMAM+CEACAM19 in diagnosis of the breast cancer were 0.868,80.0%and 88.4%;0.809,70.0%and 80.4%;0.756,97.5%and 50.9%;0.913,82.5%and 90.2%.The combined detection had the best diagnotic efficiency.Conclusion:The combined detection of serum SBEM,hMAM and CEACAM19 has high sensitivity and specificity in diagnosis of the breast cancer,which can improve the early diagnotic efficiency of the breast cancer patients.

关 键 词：乳腺肿瘤 乳腺上皮小黏蛋白 人乳腺珠蛋白 癌胚抗原相关细胞黏附分子19 

分 类 号：R737.9[医药卫生—肿瘤]